Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Reports Financial Results for Full Year 2019 and Provides Corporate Update
Successful completion of Imeglimin Phase 3 TIMES program in Japan for the treatment of type 2 diabetes in over 1,100 patients; Japanese New Drug Application (JNDA) submission on track and expected in Q3 20201 with…
Read this Press Release: Poxel Reports Financial Results for Full Year 2019 and Provides Corporate UpdatePoxel to Host Conference Call for Full Year 2019 Financial Results and Provide Corporate Update on March 26, 2020 at 2:30 pm EDT
LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel to Host Conference Call for Full Year 2019 Financial Results and Provide Corporate Update on March 26, 2020 at 2:30 pm EDTPoxel to Report Full Year 2019 Financial Results and Host Conference Call on March 26, 2020
LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel to Report Full Year 2019 Financial Results and Host Conference Call on March 26, 2020
Upcoming Events
H.C. Wainwright Annual Global Life Sciences
Kempen Life Sciences Conference
European Association for the Study of the Liver 2020 International Liver Congress
